Maze Therapeutics, Inc. has disclosed a series of stock transactions involving its Chief Executive Officer, Jason V. Coloma, in a recent SEC filing. The transactions, which occurred on November 2, 2026, are part of a Rule 10b5-1 trading plan established earlier this year. This update is significant as it highlights the financial maneuvers of a key executive in the company.

Background

Maze Therapeutics, Inc. operates within the biological products sector, specifically classified under SIC 2836, which includes biological products without diagnostic substances. The company trades under the ticker MAZE on the Nasdaq exchange. As an emerging growth company, Maze Therapeutics focuses on developing innovative therapies aimed at treating genetic diseases.

What the Filing Says

According to the filing dated November 4, 2026, Coloma reported multiple transactions involving the sale of common stock. Specifically, he sold 22,257 shares at prices ranging from approximately $29.80 to $31.70 per share. Following these transactions, Coloma retains ownership of 186,901 shares through the Coloma Family Trust and 13,301 shares through The Coloma 2021 Irrevocable Trust.

Impact

These transactions may affect investor perceptions of Maze Therapeutics, as executive stock sales can sometimes be interpreted as a lack of confidence in the company’s future. However, the sales are part of a structured trading plan, which can indicate a more strategic approach to managing personal investments. The involvement of trusts in these transactions also highlights the complexities of executive financial management.

What's Next

The filing does not say what happens next. However, continued monitoring of executive transactions may provide insights into the company’s strategic direction and financial health.